Clinical Trial Update: Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating IDX-1197 in combination with XELOX or Irinotecan for advanced gastric cancer. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• IDX-1197
• Irinotecan (Irinotecan)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Idience Co., Ltd. | Conditions: Gastric Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING